Dendritic-Cell-Based Therapeutic Cancer Vaccines

438Citations
Citations of this article
652Readers
Mendeley users who have this article in their library.

Abstract

The past decade has seen tremendous developments in novel cancer therapies through the targeting of tumor-cell-intrinsic pathways whose activity is linked to genetic alterations and the targeting of tumor-cell-extrinsic factors, such as growth factors. Furthermore, immunotherapies are entering the clinic at an unprecedented speed after the demonstration that Tcells can efficiently reject tumors and that their antitumor activity can be enhanced with antibodies against immune-regulatory molecules (checkpoint blockade). Current immunotherapy strategies include monoclonal antibodies against tumor cells or immune-regulatory molecules, cell-based therapies such as adoptive transfer of ex-vivo-activated Tcells and natural killer cells, and cancer vaccines. Herein, we discuss the immunological basis for therapeutic cancer vaccines and how the current understanding of dendritic cell and Tcell biology might enable the development of next-generation curative therapies for individuals with cancer. © 2013 Elsevier Inc.

Cite

CITATION STYLE

APA

Palucka, K., & Banchereau, J. (2013, July 25). Dendritic-Cell-Based Therapeutic Cancer Vaccines. Immunity. https://doi.org/10.1016/j.immuni.2013.07.004

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free